JPWO2022129254A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022129254A5
JPWO2022129254A5 JP2023536144A JP2023536144A JPWO2022129254A5 JP WO2022129254 A5 JPWO2022129254 A5 JP WO2022129254A5 JP 2023536144 A JP2023536144 A JP 2023536144A JP 2023536144 A JP2023536144 A JP 2023536144A JP WO2022129254 A5 JPWO2022129254 A5 JP WO2022129254A5
Authority
JP
Japan
Prior art keywords
diacid
cntatc
amide
aib
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023536144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554046A (ja
JP7767428B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/086034 external-priority patent/WO2022129254A1/en
Publication of JP2023554046A publication Critical patent/JP2023554046A/ja
Publication of JPWO2022129254A5 publication Critical patent/JPWO2022129254A5/ja
Application granted granted Critical
Publication of JP7767428B2 publication Critical patent/JP7767428B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023536144A 2020-12-16 2021-12-15 ポリペプチド及びその使用 Active JP7767428B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063125996P 2020-12-16 2020-12-16
US63/125,996 2020-12-16
PCT/EP2021/086034 WO2022129254A1 (en) 2020-12-16 2021-12-15 Polypeptides and uses thereof

Publications (3)

Publication Number Publication Date
JP2023554046A JP2023554046A (ja) 2023-12-26
JPWO2022129254A5 true JPWO2022129254A5 (enExample) 2024-10-24
JP7767428B2 JP7767428B2 (ja) 2025-11-11

Family

ID=79287870

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023536144A Active JP7767428B2 (ja) 2020-12-16 2021-12-15 ポリペプチド及びその使用

Country Status (16)

Country Link
US (3) US12371464B2 (enExample)
EP (1) EP4263586A1 (enExample)
JP (1) JP7767428B2 (enExample)
KR (1) KR20230120134A (enExample)
CN (1) CN116685599A (enExample)
AR (1) AR124391A1 (enExample)
AU (2) AU2021399076B2 (enExample)
CA (1) CA3204296A1 (enExample)
CL (1) CL2023001719A1 (enExample)
CO (1) CO2023009066A2 (enExample)
CR (1) CR20230311A (enExample)
EC (1) ECSP23052600A (enExample)
IL (1) IL303578A (enExample)
MX (1) MX2023007288A (enExample)
TW (1) TW202241933A (enExample)
WO (1) WO2022129254A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12371464B2 (en) 2020-12-16 2025-07-29 Medimmune Limited Polypeptides and uses thereof
IL304214B2 (en) 2021-01-20 2025-01-01 Viking Therapeutics Inc Compositions and methods for treating metabolic and liver disorders
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
IL322661A (en) * 2023-02-10 2025-10-01 Hangzhou Sciwind Biosciences Co Ltd Polypeptide and its history, composition containing them and their use
JP7755031B2 (ja) 2023-11-30 2025-10-15 ノヴォ ノルディスク アー／エス Ｇｌｐ－１、ｇｉｐ、およびアミリン受容体の三重作動薬
WO2025147628A2 (en) * 2024-01-05 2025-07-10 Indiana University Research And Technology Corporation Dual amylin calcitonin receptor agonists
WO2025242620A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Polypeptide combinations and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004051014A1 (de) * 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
EP1996617A2 (en) * 2006-03-15 2008-12-03 Novo Nordisk A/S Amylin derivatives
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CN102197049B (zh) * 2008-10-21 2015-03-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
US9205135B2 (en) * 2009-09-22 2015-12-08 University Of Miami Podocyte pH modulation and uses thereof
WO2013059336A1 (en) * 2011-10-18 2013-04-25 Amylin Pharmaceuticals, Llc Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties
MX2016007407A (es) * 2013-12-13 2016-12-12 Medimmune Ltd Peptidos resistentes a proteasa.
JP6730278B2 (ja) * 2014-11-27 2020-07-29 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
KR20210091705A (ko) * 2018-10-11 2021-07-22 인타르시아 세라퓨틱스 인코포레이티드 인간 아밀린 유사체 폴리펩타이드 및 사용 방법
WO2020225781A1 (en) * 2019-05-08 2020-11-12 Auckland Uniservices Limited Peptide conjugate amylin agonists and uses thereof
US12371464B2 (en) 2020-12-16 2025-07-29 Medimmune Limited Polypeptides and uses thereof

Similar Documents

Publication Publication Date Title
US12054528B2 (en) Co-agonists of the GLP-1 and amylin receptors
JP2008500281A5 (enExample)
JP6685343B2 (ja) 持続型インスリン分泌性ペプチド結合体の液状製剤
TWI428346B (zh) 新穎化合物及其等對進食行為影響
JPWO2022129254A5 (enExample)
US8114958B2 (en) Amylin family peptides
US9944687B2 (en) Compounds and their effects on feeding behaviour
JP7767428B2 (ja) ポリペプチド及びその使用
CN1145497C (zh) 肠胃外营养组合物及其制药用途
JP2019504055A5 (enExample)
US20120295836A1 (en) GLP-I Agonist And Cardiovascular Complications
WO2021136293A1 (zh) 胰岛素衍生物
JP2003522099A (ja) 遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
JP2014504597A (ja) アシル化グルカゴン類似体とインスリン類似体の組合せ物
CA2601784A1 (en) Acylated glp-1 compounds
TW200848423A (en) Glucagon/GLP-1 receptor co-agonists
WO2007133778A2 (en) Methods to restore glycemic control
WO2001066135A1 (en) Lowering serum lipids
JPWO2022129526A5 (enExample)
CN101578107B (zh) 泌酸调节肽类似物及其对进食行为的影响
BR122024023347A2 (pt) Coagonistas dos receptores glp-1 e amilina, formulação farmacêutica compreendendo os ditos coagonistas e uso terapêutico dos mesmos
WO2025054314A1 (en) Stable glp-1 analogs for the treatment of human disease and disorders
JP2018090636A (ja) 新規化合物及び摂食行動に対するそれらの効果
MX2007005274A (en) Methods for treating obesity and obesity related diseases and disorders